Prediction of the efficacy of first transarterial chemoembolization for advanced hepatocellular carcinoma via a clinical-radiomics model

Table 3 Relationships between the clinical characteristics of the training cohort and the efficacy of transarterial chemoembolization treatment, n (%)/mean ± SD

Characteristics	Effective (n = 50)	Invalid (n = 35)	P value
Sex			0.36
Male	44 (82.9)	29 (82.9)
Female	6 (17.1)	6 (17.1)
Age	55.74 ± 10.764	52.37 ± 11.014	0.163
Child-Pugh class			0.523
A	39 (78.0)	28 (80.0)
B	11 (22.0)	7 (20.0)
Hepatitis			0.511
None	2 (4)	2 (18.4)
Hepatitis B	47 (94)	32 (26.3)
Hepatitis C	1 (2)	0 (31.6)
Alcoholic hepatitis	0 (0)	1 (23.7)
PT(s)			0.090
≤ 14	49 (98.0)	31 (88.6)
> 14	1 (2.0)	4 (11.4)
TB (μmol/L)			0.567
≤ 17.1	24 (48.0)	17 (48.6)
> 17.1	26 (52.0)	18 (51.4)
ALB (g/L)			0.192
≤ 35	24 (48.0)	21 (60.0)
> 35	26 (52.0)	14 (40.0)
AST (U/L)			0.151
≤ 40	13 (26.0)	5 (14.3)
> 40	37 (74.0)	30 (85.7)
ALT (U/L)			0.463
≤ 50	34 (68.0)	25 (71.4)
> 50	16 (32.0)	10 (28.6)
AFP (ng/mL)			0.003
≤ 400	22 (44.0)	5 (14.3)
> 400	28 (56.0)	30 (85.7)

PT: Prothrombin time; TB: Total bilirubin; ALB: Albumin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; AFP: Alpha-fetoprotein.